Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

17.48 -0.02 (-0.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 292,764
Open 17.34
Bid (Size) 16.41 (1)
Ask (Size) 18.57 (1)
Prev. Close 17.50
Today's Range 16.99 - 18.11
52wk Range 10.47 - 31.45
Shares Outstanding 34,358,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Recap: RAPT Therapeutics Q3 Earnings
Via Benzinga

Performance

YTD
-6.07%
-6.07%
1 Month
+26.57%
+26.57%
3 Month
-7.85%
-7.85%
6 Month
-14.90%
-14.90%
1 Year
+6.07%
+6.07%

More News

Read More
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for RAPT Therapeutics
Via Benzinga
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Via Benzinga
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
Via Benzinga
Analyst Ratings for RAPT Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for RAPT Therapeutics's Future
Via Benzinga
Recap: RAPT Therapeutics Q1 Earnings
Via Benzinga
RAPT Therapeutics Reports First Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.